Glofitamab + Obinutuzumab

DRUG2 trials

Sponsors

French Innovative Leukemia Organisation, Liling Zhang

Conditions

LymphomaRelapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Richter Syndrome

Phase 2

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome

RecruitingNCT06186648

French Innovative Leukemia OrganisationRichter Syndrome

Start: 2024-03-21End: 2029-09-04Target: 40Updated: 2026-06-30

Hypofractionation Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse B-cell Lymphoma With Baseline High Tumor Burden

RecruitingNCT06867536

Liling ZhangLymphoma, Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Start: 2025-04-01End: 2028-08-31Target: 40Updated: 2026-05-15